Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021 2024
Previous Archive
18 July 2019 | Story Julian Roup | Photo Leonie Bolleurs
Clear glass
UFS researchers Lucas Erasmus (left), researcher in the UFS Department of Physics and Prof Hendrik Swart, senior professor in the UFS Department of Physics and SARChI chair (South African Research Chairs Initiative) in Solid State Luminescent and Advanced Materials, with the equipment used for the ground-breaking research.

A revolutionary new type of window glass – in effect a transparent solar panel - is the objective of joint research being done by the University of the Free State (UFS) in South Africa and Ghent University in Belgium. 

A working model has been created which proves the viability of the process which now needs to be refined, made more efficient and brought to the market. It is hoped to achieve this within a decade.

This new product will have the capacity to revolutionise the generation of power cheaply from the sun to power homes, factories and cities in a new clean way.

Academics from the UFS, Prof Hendrik Swart and Lucas Erasmus are doing joint research with Ghent University in Belgium, to find solutions for energy production. 

The two universities entered into an agreement recently for this research into electricity generation. The research is driven by the UFS and was prompted by ever-rising electricity prices and growing demand for electricity production. South Africa lives with constant power outages which leaves people stuck in lifts and facing chaos on the roads as traffic lights cut out. Many people who can afford them now rely on generators.

Prof Hendrik Swart, senior professor in the Department of Physics at the University of the Free State and SARChI chair (South African Research Chairs Initiative) in Solid State Luminescent and Advanced Materials, says: “An innovation like this which can help to replace traditional means of carbon based fuel for power generation in our daily lives would be hugely welcome.”

Swart explains the main objective of the research: “The idea is to develop glass that is transparent to visible light, just like the glass you find in the windows of buildings, motor vehicles and mobile electronic devices. However, by incorporating the right phosphor materials inside the glass, the light from the sun that is invisible to the human eye (ultraviolet and infrared light) can be collected, converted and concentrated to the sides of the glass panel where solar panels can be mounted. 

This invisible light can then be used to generate electricity to power buildings, vehicles and electronic devices. The goal is therefore to create a type of transparent solar panel.”

Swart says this technology can be implemented in the building environment to meet the energy demands of the people inside the buildings. “The technology is also good news for the 4.7 billion cell phone users in the world, as it can be implemented in the screens of cell phones, where the sun or the ambient light of a room can be used to power the device without affecting its appearance,” he said.

Another possible application is in electric cars, where the windows can be used to help power the vehicle.

Lucas Erasmus who is working with Prof Swart adds: “We are also looking at implementing this idea into hard, durable plastics that can act as a replacement for zinc roofs. This will allow visible diffused light to enter housing and the invisible light can then be used to generate electricity. The device also concentrates the light from a large area to the small area on the sides where the solar panels are placed; therefore, reducing the number of solar panels needed and in return, reducing the cost.”

It is envisaged that the technology will take about a decade to refine and implement. This study is currently on-going, and UFS are experimenting and testing different materials in order to optimise the device in the laboratory. It then needs to be upscaled in order to test it in the field. “It is truly the technology of the future,” says 
Erasmus.

The UFS envisages that the end result of this research will provide an attractive solution to address the energy demands of buildings, electric motor vehicles and mobile electronics without affecting their appearance. 

According to Swart, the agreement entails a joint doctoral degree in which both universities will supervise the project and the awarding of the doctorate. Lucas Erasmus, a student at the UFS, has been tasked with the assignment to conduct research at both institutions.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept